Publications

Neurofarmacologia de Sistemes

Can We Increase the Speed and Efficacy of Antidepressant Treatments? Part II. Glutamatergic and RNA Interference Strategies

Artigas F, Celada P, Bortolozzi A.,

2018

Therapeutic Potential of Conjugated siRNAs for the Treatment of Major Depressive Disorder

Artigas F, Bortolozzi A ,

2016

Subchronic vortioxetine treatment –but not escitalopram– enhances pyramidal neuron activity in the rat prefrontal cortex.

Riga MS, Teruel-Martí V, Sanchez C, Celada P, Artigas F,

2016

Glucocorticoid receptors, brain-derived neurotrophic factor, serotonin and dopamine neurotransmission are associated with interferon-induced depression

Udina M, Navinés R, Egmond E, Oriolo G, Langohr K, Gimenez D, Valdés M, Gómez-Gil E, Grande I, Gratacós M, Kapczinski F, Artigas F, Vieta E, Solà R, Martín-Santos R,

2016

A mouse model of the 15q13.3 microdeletion syndrome shows prefrontal neurophysiological dysfunctions and attentional impairment.

Nilsson S, Celada P, Fejgin K, Thelin J, Nielsen J, Santana N, Heath C, Larsen P, Nielsen V, Kent B, Robbins T, Saksida L, Stensbøl T, Bastlund J, Bussey T, Artigas F, Didriksen M ,

2016

Behavioral traits propagate across generations via segregated iterative-somatic and gametic epigenetic mechanisms

Mitchell E, Klein S, Argyropoulos KV, Sharma A, Chan RB, Toth JG, Barboza L, Bavley C, Bortolozzi A, Chen Q, Liu B, Ingenito J, Mark W, Dudakov J, Gross S, Di Paolo G, Artigas F, van den Brink M, Toth M ,

2016

Involvement of 5-HT3 receptors in the action of vortioxetine in rat brain: Focus on glutamatergic and GABAergic neurotransmission

Riga MS, Sánchez C, Celada P, Artigas F,

2016

Phencyclidine-induced disruption of oscillatory activity in prefrontal cortex: Effects of antipsychotic drugs and receptor ligands

Lladó-Pelfort L, Troyano-Rodriguez E, Van den Munkhof HE, Cervera-Ferri A, Jurado N, Núñez-Calvet M, Artigas F, Celada P ,

2016

Therapeutic antidepressant potential of a conjugated siRNA silencing the serotonin transporter after intranasal administration

Ferrés-Coy A, Galofré M, Pilar-Cuéllar F, Vidal R, Paz V, Ruiz-Bronchal E, Campa L, Pazos A, Caso JR, Leza JC, Alvarado G, Montefeltro A, Valdizán EM, Artigas F, Bortolozzi A,

2016

The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT1A and 5-HT2A receptors

Riga MS, Bortolozzi A, Campa L, Artigas F, Celada P,

2016

''VORTIOXETINE, A NOVEL ANTIDEPRESSANT WITH MULTIMODAL ACTIVITY: REVIEW OF PRECLINICAL AND CLINICAL DATA.''

SANCHEZ C, ASIN KE, ARTIGAS F.,

2015

''DEVELOPMENTS IN THE FIELD OF ANTIDEPRESSANTS, WHERE DO WE GO NOW?''

ARTIGAS F,

2015

''5-HT2A RECEPTORS ARE INVOLVED IN COGNITIVE BUT NOT ANTIDEPRESSANT EFFECTS OF FLUOXETINE.''

CASTAÑÉ A, KARGIEMAN L, CELADA P, BORTOLOZZI A, ARTIGAS F.,